Merrimack

@Eva21164205 hi

😄

We are taking a systematic approach to our preclinical development work. Learn more about our pipeline here: bit.ly/2p1NcPm

Our pipeline is shaped by understanding cancer pathways, treatments designed with pharmacological properties to match disease need, and clinical strategies with clear rationale. bit.ly/2p1NcPm

October is #BreastCancerAwareness Month. At Merrimack, we stand with everyone who has been affected by this disease and we will continue to work to develop new treatments. #BCAM

At Merrimack, innovation is at our core. Want to help us answer the tough questions? Explore our open positions and join our team today: bit.ly/2BS6JqN

Meet Daryl Drummond, Ph.D., our Head of Research. Daryl is a principal inventor for many of our nanotechnology-based candidates. bit.ly/2BUVOfS

Today we announced the receipt of a $5 million milestone payment from Shire. Read more in the full release: bit.ly/2NtzYXu

Our vision is to see a world where all cancer patients and their families can live fulfilling lives.

In case you missed our paper in @scisignal, we recently developed a multi-scale computational model that quantitatively links chemotherapy-induced DNA damage response signaling to cell fate. Read more here: bit.ly/2xvwVmW

Today we announced the completion of enrollment in our randomized Phase 2 clinical trial evaluating our lead investigational drug candidate, MM-121, in patients with heregulin positive non-small cell lung cancer. See the full release: investors.merrimack.com/node…

This week we will be attending Baird's annual Global Health Conference. Tune in to the webcast on September 6 at 8:25 a.m.: bit.ly/2oJDf6r

Innovation doesn't happen alone. Learn more about collaborating with us: bit.ly/2kHkgYd

Innovation is at our core and we've built our culture on cooperation and collaboration. Learn more about our team and explore open career opportunities: bit.ly/2kFPOxs

A cornerstone of our development strategy is to establish efficacy through clinical studies in biomarker-enriched patient populations. Learn more about our ongoing studies:Ê bit.ly/2IZaRtn

We're developing a new generation of treatments for #cancer through a focused pipeline of precise, targeted therapies. Discover more: bit.ly/2mc6MV4

Our team cares deeply about our mission and is driven by a desire to improve the lives of patients. bit.ly/2mc6MV4

Check out our paper in @scisignal exploring a multi-scale computational model we developed that quantitatively links chemotherapy-induced DNA damage response signaling to cell fate. bit.ly/2mGnThV

Our programs are backed by our systems biology expertise and a clear clinical rationale. Explore our published research and presentations: bit.ly/2mc6MV4

Check out our @scisignal paper published yesterday exploring a computational model that predicts the effects of combining chemotherapy with DNA repair inhibitors: bit.ly/2mGnThV